Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

SDS Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$683,092

92 payments

Through program year 2025, SDS Clinical Trials is reported as receiving $683,092 in research payments, across 92 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $156,022 32
2024 Research $111,575 42
2021 Research $63,981 7
2020 Research $351,515 11

Breakdown

Who paid Research payments · program years 2020–2025
  1. Imbrium Therapeutics L.P. $415,496 18 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $100,616 6 payments
  3. Avadel CNS Pharmaceuticals, LLC $86,230 2 payments
  4. Ipsen Innovation $80,750 66 payments
Studies the money was for Research payments · program years 2020–2025
  1. Oag2002 $351,515 11 payments
  2. A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of Ft218 in the Treatment of Idiopathic Hypersomnia (Ih) $86,230 2 payments
  3. A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) $84,250 2 payments
  4. A Phase 2, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of V117957 in Subjects with an Alcohol Use Disorder who are Experiencing Insomnia Associated with Alcohol Cessation $63,981 7 payments
  5. Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants $40,745 34 payments
  6. A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants $40,005 32 payments
  7. A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) $11,996 1 payment
  8. A Long-term Extension Study to Evaluate the Safety and Tolerability of TAK-861 in Participants With Selected Central Hypersomnia Conditions $4,371 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record